EP300 and prostate cancer: Notably, about half of the AR enhancers were co-occupied by p300 in prostate cancer cells, which was deterministic of stronger transcriptional activation evidenced both by higher accessibility and subsequent recruitment of the mediator and RNA polymerase II complexes.